
## Matti Annala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1666843/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. European Urology Oncology, 2022, 5, 677-686.	2.6	6
2	Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precision Oncology, 2022, 6, e2100543.	1.5	7
3	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research, 2021, 27, 1650-1662.	3.2	52
4	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research, 2021, 27, 4610-4623.	3.2	41
5	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 2021, 12, 184.	5.8	85
6	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	0.9	30
7	AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene, 2020, 39, 5241-5251.	2.6	4
8	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
9	Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histology and Histopathology, 2020, 35, 673-680.	0.5	3
10	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 573.e19-573.e29.	0.8	13
11	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncology, The, 2019, 20, 1730-1739.	5.1	227
12	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 826-836.	0.8	33
13	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-9.	1.5	26
14	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	0.9	131
15	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	7.7	376
16	Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Journal of Physical Education and Sports Management, 2018, 4, a002246.	0.5	5
17	Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nature Communications, 2018, 9, 1176.	5.8	117
18	Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications Biology, 2018, 1, 122.	2.0	21

Matti Annala

#	Article	IF	CITATIONS
19	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. British Journal of Cancer, 2018, 119, 347-356.	2.9	63
20	Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e145-e150.	0.9	1
21	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	0.9	179
22	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research, 2017, 23, 6802-6811.	3.2	69
23	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	3.2	121
24	Segmentum: a tool for copy number analysis of cancer genomes. BMC Bioinformatics, 2017, 18, 215.	1.2	7
25	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
26	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. Scientific Reports, 2017, 7, 17978.	1.6	38
27	OUP accepted manuscript. Neuro-Oncology, 2017, 19, 1206-1216.	0.6	17
28	Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. PLoS ONE, 2016, 11, e0150241.	1.1	28
29	Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Journal of Physical Education and Sports Management, 2016, 2, a000752.	0.5	24
30	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1598.	3.4	290
31	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e233-e236.	0.9	15
32	Epigenetically altered miRâ€193b targets cyclin D1 in prostate cancer. Cancer Medicine, 2015, 4, 1417-1425.	1.3	39
33	The evolutionary history of lethal metastatic prostate cancer. Nature, 2015, 520, 353-357.	13.7	1,185
34	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	13.5	2,435
35	Transcriptome Sequencing Reveals <i>PCAT5</i> as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. Cancer Research, 2015, 75, 4026-4031.	0.4	68
36	Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. Oncotarget, 2015, 6, 6235-6250.	0.8	23

#	Article	IF	CITATIONS
37	DOT1Lâ€HES6 fusion drives androgen independent growth in prostate cancer. EMBO Molecular Medicine, 2014, 6, 1121-1123.	3.3	17